These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 35335032)

  • 21. The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2.
    Ho TC; Chen YA; Chan HP; Chang CC; Chuang KP; Lee CH; Yuan CH; Tyan YC; Yang MH
    Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2.
    Reiter R; Von Blanckenburg P; Mutters R; Thiemer J; Geßner R; Seifart U
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects.
    Fabricius D; Ludwig C; Scholz J; Rode I; Tsamadou C; Jacobsen EM; Winkelmann M; Grempels A; Lotfi R; Janda A; Körper S; Adler G; Debatin KM; Schrezenmeier H; Jahrsdörfer B
    Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Antibody Response to Heterologous Prime-Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study.
    Firinu D; Perra A; Campagna M; Littera R; Meloni F; Sedda F; Conti M; Costanzo G; Erbi M; Usai G; Locci C; Carta MG; Cappai R; Orrù G; Del Giacco S; Coghe F; Chessa L
    Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies.
    Shehab M; Alrashed F; Alfadhli A; Alotaibi K; Alsahli A; Mohammad H; Cherian P; Al-Khairi I; Alphonse Thanaraj T; Channanath A; Ali H; Abu-Farha M; Abubaker J; Al-Mulla F
    Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960217
    [No Abstract]   [Full Text] [Related]  

  • 26. Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination.
    Geers D; Sablerolles RSG; van Baarle D; Kootstra NA; Rietdijk WJR; Schmitz KS; Gommers L; Bogers S; Nieuwkoop NJ; van Dijk LLA; van Haren E; Lafeber M; Dalm VASH; Goorhuis A; Postma DF; Visser LG; Huckriede ALW; Sette A; Grifoni A; de Swart RL; Koopmans MPG; van der Kuy PHM; GeurtsvanKessel CH; de Vries RD;
    iScience; 2023 Jan; 26(1):105753. PubMed ID: 36507223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines.
    Kim JY; Bae S; Park S; Kwon JS; Lim SY; Park JY; Cha HH; Seo MH; Lee HJ; Lee N; Heo J; Shum D; Jee Y; Kim SH
    Immune Netw; 2021 Aug; 21(4):e29. PubMed ID: 34522442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination.
    Schmidt T; Klemis V; Schub D; Mihm J; Hielscher F; Marx S; Abu-Omar A; Ziegler L; Guckelmus C; Urschel R; Schneitler S; Becker SL; Gärtner BC; Sester U; Sester M
    Nat Med; 2021 Sep; 27(9):1530-1535. PubMed ID: 34312554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
    Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Blanc PG; Gwira Baumblatt JA; Woo EJ; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):249-254. PubMed ID: 35176008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period.
    Kim JY; Lim SY; Park S; Kwon JS; Bae S; Park JY; Cha HH; Seo MH; Lee HJ; Lee N; Kim K; Shum D; Jee Y; Kim SH
    J Infect Dis; 2022 Mar; 225(5):777-784. PubMed ID: 34850034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines.
    Szczepanek J; Skorupa M; Goroncy A; Jarkiewicz-Tretyn J; Wypych A; Sandomierz D; Jarkiewicz-Tretyn A; Dejewska J; Ciechanowska K; Pałgan K; Rajewski P; Tretyn A
    Vaccines (Basel); 2022 Jan; 10(1):. PubMed ID: 35062760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
    Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
    Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.
    Barros-Martins J; Hammerschmidt SI; Cossmann A; Odak I; Stankov MV; Morillas Ramos G; Dopfer-Jablonka A; Heidemann A; Ritter C; Friedrichsen M; Schultze-Florey C; Ravens I; Willenzon S; Bubke A; Ristenpart J; Janssen A; Ssebyatika G; Bernhardt G; Münch J; Hoffmann M; Pöhlmann S; Krey T; Bošnjak B; Förster R; Behrens GMN
    Nat Med; 2021 Sep; 27(9):1525-1529. PubMed ID: 34262158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees.
    Alghamdi AN; Alotaibi MI; Alqahtani AS; Al Aboud D; Abdel-Moneim AS
    Front Med (Lausanne); 2021; 8():760047. PubMed ID: 34692740
    [No Abstract]   [Full Text] [Related]  

  • 36. Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data.
    Paris C; Perrin S; Hamonic S; Bourget B; Roué C; Brassard O; Tadié E; Gicquel V; Bénézit F; Thibault V; Garlantézec R; Tattevin P
    Clin Microbiol Infect; 2021 Nov; 27(11):1699.e5-1699.e8. PubMed ID: 34265462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of ChAdOx1 nCoV-19 Booster Vaccination Following Two CoronaVac Shots in Healthcare Workers.
    Prasithsirikul W; Pongpirul K; Nopsopon T; Phutrakool P; Pongpirul W; Samuthpongtorn C; Suwanwattana P; Jongkaewwattana A
    Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions.
    Lee SW; Moon JY; Lee SK; Lee H; Moon S; Chung SJ; Yeo Y; Park TS; Park DW; Kim TH; Sohn JW; Yoon HJ; Kim SH
    Front Immunol; 2021; 12():779212. PubMed ID: 34899739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
    Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
    ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Humoral and Cellular Responses to COVID-19 Vaccines in SARS-CoV-2 Infection-Naïve and -Recovered Korean Individuals.
    Hwang JY; Kim Y; Lee KM; Jang EJ; Woo CH; Hong CU; Choi ST; Xayaheuang S; Jang JG; Ahn JH; Park H
    Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.